343 related articles for article (PubMed ID: 23375472)
1. Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: comparison in two siblings.
Tajima G; Sakura N; Kosuga M; Okuyama T; Kobayashi M
Mol Genet Metab; 2013 Mar; 108(3):172-7. PubMed ID: 23375472
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up.
Tylki-Szymanska A; Jurecka A; Zuber Z; Rozdzynska A; Marucha J; Czartoryska B
Acta Paediatr; 2012 Jan; 101(1):e42-7. PubMed ID: 21672014
[TBL] [Abstract][Full Text] [Related]
3. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
[TBL] [Abstract][Full Text] [Related]
4. Idursulfase enzyme replacement therapy in an adult patient with severe Hunter syndrome having a novel mutation of iduronate-2-sulfatase gene.
Christianto A; Watanabe H; Nakajima T; Inazu T
Clin Chim Acta; 2013 Aug; 423():66-8. PubMed ID: 23726270
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS).
Muenzer J; Botha J; Harmatz P; Giugliani R; Kampmann C; Burton BK
Orphanet J Rare Dis; 2021 Oct; 16(1):456. PubMed ID: 34717704
[TBL] [Abstract][Full Text] [Related]
6. [Early response to idursulfase in a 31-year old male patient with Hunter syndrome].
Pérez-Calvo J; Bergua Sanclemente I; López Moreno MJ; Torralba Cabeza MÁ; Amores Arriaga B
Rev Clin Esp; 2011; 211(7):e42-5. PubMed ID: 21524741
[TBL] [Abstract][Full Text] [Related]
7. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
[TBL] [Abstract][Full Text] [Related]
8. Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome).
Papadia F; Lozupone MS; Gaeta A; Capodiferro D; Lacalendola G
Eur Rev Med Pharmacol Sci; 2011 Mar; 15(3):253-8. PubMed ID: 21528770
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI.
Furujo M; Kubo T; Kosuga M; Okuyama T
Mol Genet Metab; 2011 Dec; 104(4):597-602. PubMed ID: 21930407
[TBL] [Abstract][Full Text] [Related]
10. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
Whiteman DA; Kimura A
Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
[TBL] [Abstract][Full Text] [Related]
11. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II.
Schulze-Frenking G; Jones SA; Roberts J; Beck M; Wraith JE
J Inherit Metab Dis; 2011 Feb; 34(1):203-8. PubMed ID: 20978944
[TBL] [Abstract][Full Text] [Related]
12. The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II.
Żuber Z; Różdżyńska-Świątkowska A; Jurecka A; Tylki-Szymańska A
PLoS One; 2014; 9(1):e85074. PubMed ID: 24454794
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
[TBL] [Abstract][Full Text] [Related]
14. Hunter syndrome in an 11-year old girl on enzyme replacement therapy with idursulfase: brain magnetic resonance imaging features and evolution.
Manara R; Rampazzo A; Cananzi M; Salviati L; Mardari R; Drigo P; Tomanin R; Gasparotto N; Priante E; Scarpa M
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S67-72. PubMed ID: 20052546
[TBL] [Abstract][Full Text] [Related]
15. A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry.
Racoma MJC; Calibag MKKB; Cordero CP; Abacan MAR; Chiong MAD
Orphanet J Rare Dis; 2021 Jul; 16(1):323. PubMed ID: 34289859
[TBL] [Abstract][Full Text] [Related]
16. Idursulfase in Hunter syndrome treatment.
Zareba G
Drugs Today (Barc); 2007 Nov; 43(11):759-67. PubMed ID: 18174963
[TBL] [Abstract][Full Text] [Related]
17. Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature.
Jurecka A; Żuberuber Z; Opoka-Winiarska V; Węgrzyn G; Tylki-Szymańska A
Mol Genet Metab; 2012 Nov; 107(3):508-12. PubMed ID: 22926198
[TBL] [Abstract][Full Text] [Related]
18. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS).
Burton BK; Whiteman DA;
Mol Genet Metab; 2011 Jun; 103(2):113-20. PubMed ID: 21439875
[TBL] [Abstract][Full Text] [Related]
19. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.
Barbier AJ; Bielefeld B; Whiteman DA; Natarajan M; Pano A; Amato DA
Mol Genet Metab; 2013 Nov; 110(3):303-10. PubMed ID: 23988379
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
Wraith JE
Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
